GH Research

GHRS

Market cap $890M

14.35 USD

+0.60

4.36%

At close Updated Nov 19, 3:59 PM EST

Pre-market

After hours

14.38

+0.03

0.21%

1 day

4.36%

5 days

-2.91%

1 month

2.5%

3 months

14.34%

6 months

22.65%

Year to date

81.42%

1 year

49.32%

5 years

-25.45%

10 years

-25.45%

About: GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Employees: 50

Healthcare Biotechnology